You are viewing a javascript disabled version of the site. Please enable Javascript for this site to function properly.
Go to headerGo to navigationGo to searchGo to contentsGo to footer
In content section. Select this link to jump to navigation

Multiplex Screen of Serum Biomarkers in Facioscapulohumeral Muscular Dystrophy

Article type: Research Article

Authors: Statland, Jeffrey; | Donlin-Smith, Colleen M. | Tapscott, Stephen J. | van der Maarel, Silvère M. | Tawil, Rabi

Affiliations: Department of Neurology, University of Kansas Medical Center, Kansas City, KS, USA | Department of Neurology, University of Rochester Medical Center, Rochester, NY, USA | Division of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, WA, USA | Department of Human Genetics, Leiden University Medical Center, Leiden, Netherlands

Note: [] Correspondence to: Jeffrey M. Statland, MD, 4330 Shawnee Mission Parkway, Ste 323, Fairway, KS 66205, USA. Tel.: +1 913 945 9933; Fax: +1 913 588 6965; E-mails: jstatland@kumc.edu; Colleen_Donlin-Smith@URMC.Rochester.edu (C.M. Donlin-Smith); stapscot@fhcrc.org (S.J Tapscott); S.M.van_der_Maarel@lumc.nl (S. van der Maarel); Rabi_Tawil@URMC.Rochester.edu (R. Tawil).

Keywords: Muscle Disease, facioscapulohumeral muscular dystrophy, DUX4, biomarker, proteomics

DOI: 10.3233/JND-140034

Journal: Journal of Neuromuscular Diseases, vol. 1, no. 2, pp. 181-190, 2014

Published: 2014
Get PDF open access
Supplementary Materials:

Supplementary Tables.

Abstract

Background: Recent studies have proposed a unified genetic model for Facioscapulohumeral muscular dystrophy (FSHD), identifying potential therapeutic targets for future clinical trials. Serum biomarkers related to disease activity will be important for proof of concept or early phase clinical studies. Objective: To identify potential serum biomarkers in FSHD for possible use in future clinical trials. Methods: We performed a prospective cross-sectional study of serum biomarkers in 22 FSHD patients (19 FSHD1, 3 FSHD2) compared to 23 age and gender-matched healthy controls using a commercial multiplex, microsphere-based immune-fluorescent assay of 243 markers (Myriad, Human Discovery MAP 250, v2.0). Results: 169 markers had values sufficient for analysis. Correction for multiple testing identified 7 biomarkers below a 5% false discovery rate: creatine kinase MB fraction (CKMB, 6.52 fold change, P < 0.0001), tissue-type plasminogen activator (PLAT, 1.64 fold change, P < 0.0001), myoglobin (2.23 fold change, P = 0.0001), epidermal growth factor (EGF, 2.33 fold change, P = 0.0004), chemokine (C-C motif) ligand 2 (1.48 fold change, P = 0.0004), CD 40 ligand (1.89 fold change, P = 0.001), and vitronectin (VTN, 1.28 fold change, P = 0.001). Moderate correlations to measures of FSHD disease were seen for CKMB, PLAT, and EGF. Markers in the plasminogen pathway (PLAT and VTN) were correlated with each other in FSHD but not healthy controls. Conclusions: Commercial multiplex immune-fluorescent screening is a potentially powerful tool for identifying biomarkers for future FSHD therapeutic trials. Biomarkers identified in this study warrant further study in a larger prospective validation study.

Show less